Jean-Sébastien Claveau, MD, of Maisonneuve-Rosemont Hospital at the University of Montreal, spoke with SOHO Insider at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, California, on a poster abstract he presented, titled: “Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma.”
Dr. Claveau explained that according to the International Myeloma Working Group clinicians need to perform “two assessments to confirm that patient is progressing before changing treatment.” The study evaluated whether it is necessary for clinicians to repeat biomarker tests to confirm progressive disease when two biomarkers already meet the criteria for disease progression.
Using simultaneous criteria accurately identifies disease progression in relapsed myeloma without needing biomarker confirmation, Dr. Claveau and colleagues concluded in the study.
“We showed that the simultaneous criteria allow to identify patients with true progressive disease without overestimating the progression rate of myeloma,” the investigators wrote in the abstract.
Reference
Claveau JS, Dispenzieri, A, Kapoor P. Eliminating the need for sequential confirmation of response in multiple myeloma. Abstract #653. Presented at the 66th American Society of Hematology Annual Meeting and Exposition. December 7-10; San Diego, California.
